Health Canada approves Ipsen’s Sohonos™ (palovarotene capsules) as the first approved treatment for progressive fibrodysplasia ossificans

PARIS, January 24, 2022–(BUSINESS WIRE)–Regulatory news:

Ipsen (Euronext: IPN; ADR: IPSEY) today announced Health Canada’s approval of Sohonos (palovarotene capsules), a selective oral retinoic acid receptor gamma (RARγ) agonist indicated to reduce the formation of heterotopic ossification (HO; new bone formation) in adults and children aged 8 years and older for women and 10 years and older for men with fibrodysplasia ossificans progressiva (FOP).1 Sohonos is approved for the treatment of patients with FOP for both chronic use and for flare-ups in these patient populations. This decision marks the first approval of Sohonos in the world.

Dr Howard Mayer, Executive Vice President and Head of Research and Development, Ipsen, said, “FOP is a progressive and debilitating disease that has such a profound impact on patients and their families. Until today, there were no approved drugs, and we are proud to bring this important new drug to the FOP community.

FOP is characterized by new bone formation outside of the normal skeletal system, such as in the soft connective tissues, a process known as heterotopic ossification,2 which may be preceded by painful soft tissue swelling or “flare-ups”.2 Pushing episodes are common and contribute substantially to the formation of new bone, but bone can also form in the absence of pushing. Once formed, it is irreversible and leads to loss of mobility and shortened life expectancy.2 It is an ultra-rare genetic disease with an estimated prevalence of 1.36 per million individuals; however, the number of confirmed cases varies by country.3.4.

As part of its continued commitment to the FOP and rare disease community, Ipsen expects to file an application in the United States in the first half of 2022 and is in discussions with other regulatory authorities around the world.

About the MOVE Clinical Program
This approval is based on data from the ongoing MOVE trial, the world’s first multicenter Phase III FOP trial. MOVE is a single-arm, open-label trial evaluating the efficacy and safety of a chronic/flare dosing regimen of palovarotene to reduce new annualized HO volume in patients with FOP

About Sohonos Sohonos is an oral, selective RARγ agonist developed as a treatment for people living with the ultra-rare debilitating genetic disease, FOP. The treatment was acquired by Ipsen through the acquisition of Clementia Pharmaceuticals in April 2019. It is part of the class of retinoid drugs associated with birth defects in humans. Sohonos should not be used by patients who are or intend to become pregnant due to the risk of teratogenicity. To minimize fetal exposure, Sohonos should only be administered if all conditions for pregnancy prevention are met. Sohonos has been shown to cause premature physisal closure in growing children with FOP; periodic monitoring is recommended.

About Ipsen
Ipsen is a mid-market international biopharmaceutical company specializing in transformative medicines in oncology, rare diseases and neurosciences; it also has a well-established Consumer Healthcare business. With total sales of more than €2.5 billion in fiscal year 2020, Ipsen markets more than 20 medicines in more than 115 countries, with a direct commercial presence in more than 30 countries. The Company’s research and development efforts focus on its innovative and differentiating technological platforms located at the heart of major biotechnology and life sciences hubs: Paris-Saclay, France; Oxford, UK; Cambridge, USA; Shanghai, China. Ipsen has approximately 5,700 employees worldwide and is listed in Paris (Euronext: IPN) and in the United States via a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit

Forward-looking statement
The forward-looking statements, objectives and targets contained in this document are based on the Group’s management strategy, its current opinions and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial objectives, which were set under reasonable macroeconomic conditions based on the information available today. The use of the words “believes”, “anticipates” and “expects” and similar expressions is intended to identify forward-looking statements, including the Group’s expectations regarding future events, including filings and decisions regulations, and the results of this study or other studies. . Furthermore, the objectives described in this document were established without taking into account assumptions of external growth and possible future acquisitions, which could modify these parameters. These objectives are based on data and assumptions considered reasonable by the Group. These objectives depend on conditions or facts likely to occur in the future, and not exclusively on historical data. Actual results could differ materially from these objectives given the occurrence of certain risks and uncertainties, including the fact that a promising product in the early development or clinical trial phase may never be brought to market. or achieve its business objectives, including for regulatory or competitive reasons. The Group must or could face competition from generic products which could result in a loss of market share. Furthermore, the Research and Development process comprises several stages, each of which carries a substantial risk that the Group will not achieve its objectives and be forced to abandon its efforts on a product in which it has invested significant sums. Thus, the Group cannot be certain that favorable results obtained during preclinical trials will be confirmed later during clinical trials, nor that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantee that a product will receive the necessary regulatory approvals or that the product will prove to be a commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward health care cost containment; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the Group’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in ways that could harm the Group’s activities and financial results. The Group cannot be certain that its partners will fulfill their obligations. He might not be able to get any benefit from these deals. Failure of one of the Group’s partners could generate lower revenues than forecast. Such situations could have an adverse effect on the Group’s business, financial situation or results. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, objectives or estimates contained in this press release to reflect any change in the events, conditions, assumptions or circumstances on which such statements are based, except as required by applicable law. The Group’s activity is subject to the risk factors described in its reference documents filed with the Autorité des Marchés Financiers. The risks and uncertainties presented are not exhaustive and the reader is invited to refer to the Group’s 2020 Universal Registration Document available on its website (

1 Data on file
2 Kaplan FS, et al. The medical management of fibrodysplasia ossificans progressiva: current therapeutic considerations. Proc Intl Clin Council FOP 1:1-111, 2019.
3 Lilijestrom, M & Bogard, B 2016, “The World Population Known for FOP”, FOP Drug Development Forum, Boston, MA, October 24-25.
4 Baujat et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a linkage of records from two national databases. Orphanet review of rare diseases. 2017; 12:123.

See the source version on


Craig Brands
Vice President, Investor Relations
+44 7584 349 193

Adrien Dupin de Saint-Cyr
Investor Relations Manager
+33 6 64 26 17 49

michelle cammack
Global Communications
+44 7768 502091

Maryanne Quinn
Communications North America
+1 857 529 1151

Comments are closed.